These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 16900207)

  • 1. Oncogenic kinases of myeloproliferative disorders induce both protein synthesis and G1 activators.
    Lelièvre H; Cervera N; Finetti P; Delhommeau F; Vainchenker W; Bertucci F; Birnbaum D
    Leukemia; 2006 Oct; 20(10):1885-8. PubMed ID: 16900207
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloproliferative disorders: premalignant, stem cell, G1 diseases?
    Lelièvre H; Ferrand A; Mozziconacci MJ; Birnbaum D; Delaval B
    Leukemia; 2006 Sep; 20(9):1475-80. PubMed ID: 16810200
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome.
    Delaval B; Létard S; Lelièvre H; Chevrier V; Daviet L; Dubreuil P; Birnbaum D
    Cancer Res; 2005 Aug; 65(16):7231-40. PubMed ID: 16103074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB.
    Ma S; Liu MA; Yuan YL; Erikson RL
    Mol Cancer Res; 2003 Mar; 1(5):376-84. PubMed ID: 12651910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BUBR1 phosphorylation is regulated during mitotic checkpoint activation.
    Li W; Lan Z; Wu H; Wu S; Meadows J; Chen J; Zhu V; Dai W
    Cell Growth Differ; 1999 Nov; 10(11):769-75. PubMed ID: 10593653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the role of JAK2(V617F) mutation in leukemic transformation of myeloproliferative neoplasms?
    Lopes da Silva R; Ribeiro P; Lourenço A; Santos SC; Santos M; Costa I; de Sousa AB
    Lab Hematol; 2011 Mar; 17(1):12-6. PubMed ID: 21421540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
    Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
    Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Greiner TC
    Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
    [No Abstract]   [Full Text] [Related]  

  • 10. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
    el-Deiry WS; Harper JW; O'Connor PM; Velculescu VE; Canman CE; Jackman J; Pietenpol JA; Burrell M; Hill DE; Wang Y
    Cancer Res; 1994 Mar; 54(5):1169-74. PubMed ID: 8118801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
    Dunlap J; Kelemen K; Leeborg N; Braziel R; Olson S; Press R; Huang J; Gatter K; Loriaux M; Fan G
    Am J Clin Pathol; 2011 May; 135(5):709-19. PubMed ID: 21502425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
    Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
    Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
    Kim YK; Shin MG; Kim HR; Yang DH; Cho SH; Lee JJ; Chung IJ; Ryang DW; Kim HJ
    Leuk Res; 2008 Jun; 32(6):993-5. PubMed ID: 18055011
    [No Abstract]   [Full Text] [Related]  

  • 14. [JAK2 mutation in myeloproliferative disorders].
    Inokuchi K
    Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
    [No Abstract]   [Full Text] [Related]  

  • 15. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
    Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
    Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
    [No Abstract]   [Full Text] [Related]  

  • 17. Myelodysplastic/myeloproliferative disorders.
    Malcovati L; Cazzola M
    Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes.
    Lasho TL; Mesa R; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143
    [No Abstract]   [Full Text] [Related]  

  • 19. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
    Bousquet M; Brousset P
    Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
    [No Abstract]   [Full Text] [Related]  

  • 20. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders.
    Cazzola M; Skoda R
    Haematologica; 2005 Jul; 90(7):871-4. PubMed ID: 15996923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.